Otsuka

Former CEO of Proteus reflects on the dramatic fall of ‘digital pill’ unicorn

  • by

The US healthcare system’s focus on activity rather than value for money was behind the demise of Proteus Digital Health and its “digital pill”, which measured whether schizophrenia patients took their meds, according to the company’s former CEO. At the Frontiers Health conference Andrew Thompson… Read More »Former CEO of Proteus reflects on the dramatic fall of ‘digital pill’ unicorn

To avoid crisis, pharma must address costs

  • by

Scrutiny of drug prices will continue whether Trump or Biden wins. But pharma can take steps to address critics and cut costs before they reach a crisis point, according to a panel of industry experts.

Otsuka Inqovi (decitabine and cedazuridine) Received the US FDA’s Approval to MDS and CMML

  • by

Shots: The approval was based on P-III trial from the ASCERTAIN study supporting P-I and P-II clinical studies which evaluated the safety and efficacy including decitabine exposure equivalence in oral Inqovi vs intravenous decitabine Otsuka a subsidiary of Astex Pharmaceuticals with its partner Taiho Pharmaceutical… Read More »Otsuka Inqovi (decitabine and cedazuridine) Received the US FDA’s Approval to MDS and CMML

Court approves Otsuka’s bid to buy Proteus for $15M

  • by

A bankruptcy court in Delaware approved a stalking-horse bid from Otsuka to acquire Proteus Digital Health for $15 million. The company, which makes sensor that can be embedded in pills to track medication adherence, filed for bankruptcy in June.